Post-diagnosis aspirin use and survival in veterans with head and neck cancer.
Citation: Head & Neck. 41(5):1220-1226, 2019 05.PMID: 30537085Institution: MedStar Health Research Institute | MedStar Washington Hospital CenterDepartment: OtolaryngologyForm of publication: Journal ArticleMedline article type(s): Journal ArticleSubject headings: *Aspirin/tu [Therapeutic Use] | *Carcinoma, Squamous Cell/dt [Drug Therapy] | *Head and Neck Neoplasms/dt [Drug Therapy] | *Veterans | Aged | Carcinoma, Squamous Cell/mo [Mortality] | Female | Head and Neck Neoplasms/mo [Mortality] | Humans | Kaplan-Meier Estimate | Male | Middle Aged | Multivariate Analysis | Retrospective Studies | Survival Analysis | United StatesYear: 2019Local holdings: Available online from MWHC library: 1996 - presentISSN:- 1043-3074
- Lumley, Catherine J:
- https://orcid.org/0000-0001-8609-9002
Item type | Current library | Collection | Call number | Status | Date due | Barcode |
---|---|---|---|---|---|---|
Journal Article | MedStar Authors Catalog | Article | 30537085 | Available | 30537085 |
Available online from MWHC library: 1996 - present
BACKGROUND: Our objective was to determine the effect of post-diagnosis aspirin use on survival in veterans with head and neck squamous cell carcinoma.
CONCLUSION: Aspirin use following diagnosis and curative treatment of head and neck squamous cell carcinoma is associated with improved OS and DSS.
Copyright (c) 2018 Wiley Periodicals, Inc.
METHODS: Retrospective cohort study of 584 veterans with head and neck squamous cell carcinoma treated at the Washington DC VA Medical Center between 1995 and 2015. Charts were queried for clinical-pathologic data, aspirin prescriptions, and outcome. The Kaplan-Meier method was used to determine overall survival (OS) and disease-specific survival (DSS) among aspirin users and nonusers.
RESULTS: A total of 329 patients met inclusion criteria. Primary subsites included oropharynx (n = 143), larynx (n = 105), oral cavity (n = 62), and hypopharynx (n = 19). Eighty-four patients were aspirin users (25.5%). Aspirin users demonstrated significantly better 3-year OS and DSS (78.6% and 88.1%) compared to nonaspirin users (OS: 55.9% and DSS: 70.2%; P = .0003 and P = .0019, respectively). On multivariate analysis, aspirin use remained independently associated with improved survival.
English